2021
Minimal Toxicity Seen When Pembrolizumab Is Added to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: Early Results from an Ongoing Phase II Trial (ECOG-ACRIN EA9171)
Zeidan A, Roopcharan K, Radich J, Bewersdorf J, Bhatt V, Sharon E, Little R, Gore S, Caldwell A, Luger S, Litzow M. Minimal Toxicity Seen When Pembrolizumab Is Added to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: Early Results from an Ongoing Phase II Trial (ECOG-ACRIN EA9171). Blood 2021, 138: 3613. DOI: 10.1182/blood-2021-145015.Peer-Reviewed Original ResearchUndetectable minimal residual diseaseClinical Trials CommitteeTherapy-free remissionCombination of TKIG3 adverse eventsImmune-related AEAdverse eventsTrials CommitteeMinimal residual diseaseSafety cohortTKI discontinuationTKI therapyPD-L1Residual diseasePilot phase II clinical trialPD-1/PD-L1Detectable minimal residual diseaseImmune-related adverse eventsNon-hematologic adverse eventsAnti-PD-1 antibodyOngoing phase II trialBCR-ABLPhase II clinical trialAdvisory CommitteeDaiichi Sankyo
2020
Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171)
Zeidan A, Wang V, Radich J, Bewersdorf J, Bhatt V, Sharon E, Gore S, Luger S, Litzow M. Blast MRD CML 1 Trial: Blockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease (MRD) in Chronic Myeloid Leukemia (CML)- a Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease: A Trial of the ECOG-ACRIN Cancer Research Group (EA9171). Blood 2020, 136: 1. DOI: 10.1182/blood-2020-137734.Peer-Reviewed Original ResearchUndetectable minimal residual diseaseChronic myeloid leukemiaMeasurable residual diseaseTyrosine kinase inhibitorsTKI discontinuationTKI therapyMinimal residual diseaseCML patientsResidual diseaseMyeloid leukemiaBristol-Myers SquibbPembrolizumab therapyAdverse eventsPD-1T cellsCML cellsAnti-PD-1/PD-L1 therapyBlast phase chronic myeloid leukemiaPilot phase II clinical trialThird-line tyrosine kinase inhibitorsAllogeneic hematopoietic stem cell transplantAnti-PD-1 monoclonal antibodyPD-1/PD-L1Anti-PD-1 pembrolizumabDetectable minimal residual disease
2011
Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia
Park E, Gang EJ, Hsieh YT, Schaefer P, Chae S, Klemm L, Huantes S, Loh M, Conway EM, Kang ES, Koo H, Hofmann WK, Heisterkamp N, Pelus L, Keerthivasan G, Crispino J, Kahn M, Müschen M, Kim YM. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia. Blood 2011, 118: 2191-2199. PMID: 21715311, PMCID: PMC3162353, DOI: 10.1182/blood-2011-04-351239.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCombined Modality TherapyDrug Resistance, NeoplasmGene ExpressionGene TargetingHumansInhibitor of Apoptosis ProteinsMiceMice, Inbred NODMice, KnockoutNeoplasm, ResidualOligonucleotidesPrecursor Cell Lymphoblastic Leukemia-LymphomaRepressor ProteinsRNA, Small InterferingSurvivinTumor Stem Cell AssayXenograft Model Antitumor AssaysConceptsAcute lymphoblastic leukemiaDrug resistanceLymphoblastic leukemiaDrug-resistant acute lymphoblastic leukemiaDetectable minimal residual diseasePrimary acute lymphoblastic leukemiaNucleic acid antisense oligonucleotideMinimal residual diseaseInhibition of survivinResidual diseaseSurvival advantageXenograft modelSurvivin expressionSurvivin inhibitionLeukemiaSurvivinChemotherapyRelapseAntisense oligonucleotideSurvivin/BIRC5Present studyApoptosis proteinInhibitionCellsPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply